Saturday 17 October 2026 Export EBS’s income statement to Excel — free account

Emergent Biosolutions Inc.

EBS Healthcare Drug Manufacturers Specialty & Generic

Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.

6.38 0.80 −11.14%

Follow EBS

Alert me

Market cap: $368.1M
P/E: 0.0×
Fwd P/E: −26.5×
Dividend yield: —
F-score: 6/9
Altman Z: 1.63
Beneish M: −3.56
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.26

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	—	—	—	2	3	—	1	—	—	2

Insider Ownership 6.55%

Capital & Financial Ratios $m

Market Cap 368.14

Revenue 770.20

Net Income (176.80)

Free Cash Flow 86.10

Net Debt 440.90

Current Ratio 5.42

Debt/Equity 1.70

P/E ratio 0.00

Fwd P/E (26.50)

P/S ratio 0.43

P/B ratio 0.96

Past 5Y EPS Growth (30.34%)

This Y EPS Growth (76.50%)

Next Y EPS Growth 190.99%

Next Y revenue growth (11.55%)

Next 5Y EPS Growth 0.83%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 18.65%

10-year low 10-year high

P/B against its own 10 years 30.89%

10-year low 10-year high

EV/Sales against its own 10 years 18.02%

10-year low 10-year high

EV/FCF against its own 10 years 17.45%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	112	106	209	141
Receivables	191	155	84	190
Inventory	329	312	343	304
Other	—	—	—	6
	680	599	663	666

	2023	2024	2025	Q'26
Payables	112	61	56	50
ST’ Debt	414	—	—	—
Other	33	22	16	10
	651	162	132	123

Compound Annual Growth %

	10y	5y	3y
Sales	4.26%	(13.74%)	(12.72%)
Cash Flow	14.91%	(20.46%)	0.00%
Earnings	(1.77%)	(29.64%)	0.00%
Book Value	(2.31%)	(18.43%)	(27.79%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	156	234	—	—	—
’25	222	141	231	149	743
’24	300	255	294	195	1,044
’23	164	338	271	277	1,049
’22	308	243	240	327	1,118
’21	343	398	329	704	1,774
’20	193	395	385	583	1,555

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(34)	56	—	—	—
’25	(11)	106	(2)	78	171
’24	(63)	48	154	(80)	59
’23	(184)	(114)	60	32	(206)
’22	(37)	(16)	(74)	93	(34)
’21	5	(30)	17	328	320
’20	58	128	105	245	536

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(36)	54	—	—	—
’25	23	104	(6)	74	195
’24	(73)	43	156	(81)	44
’23	(199)	(127)	47	21	(258)
’22	(69)	(48)	(102)	69	(172)
’21	(51)	(97)	(38)	282	96
’20	34	93	60	209	395

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.12	(3.49)	—	—	—
’25	1.19	(0.22)	0.91	(1.04)	0.93
’24	0.17	(5.38)	2.06	(0.58)	(3.60)
’23	(3.65)	(5.15)	(5.08)	(0.95)	(14.85)
’22	(0.07)	(1.13)	(1.52)	(1.28)	(4.47)
’21	1.28	0.09	(0.61)	3.50	4.27
’20	(0.24)	1.73	0.73	3.44	5.67

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	24.47	27.94	42.67	39.11	46.37	29.88	10.61	1.81	1.42	4.02	Analyst estimates 2026–2028 Powerpack
	High	44.38	47.90	73.89	67.45	137.61	127.20	52.28	16.66	15.10	13.41
People
People	Employees	1,098	1,256	1,705	1,834	2,200	2,416	2,500	1,600	900	900
	Revenue/emp, $m	0.45	0.45	0.46	0.60	0.71	0.73	0.45	0.66	1.16	0.83
Income, $m
Income, $m	Revenue	489	561	782	1,106	1,555	1,774	1,118	1,049	1,044	743
	Gross margin, %	74.16	66.54	58.81	60.80	66.31	57.82	37.98	32.77	34.72	56.09
	EBT	99	119	82	77	407	303	(219)	(731)	(143)	83
	EBT margin, %	20.29	21.14	10.42	7.00	26.18	17.10	(19.60)	(69.68)	(13.69)	11.15
	Net income	52	83	63	55	305	220	(212)	(760)	(191)	53
	Depreciation	38	44	63	114	118	170	154	365	116	106
Per share, $
Per share, $	Revenue	12.16	13.42	15.62	21.48	29.51	33.15	22.31	20.49	19.69	13.89
	Earnings	1.29	1.98	1.25	1.06	5.79	4.32	(4.47)	(14.85)	(3.60)	0.98
	Cash flow	1.36	4.98	0.83	3.65	10.17	5.99	(0.68)	(4.03)	1.11	3.19
	Capex	(1.90)	(1.31)	(1.39)	(1.69)	(2.68)	(4.19)	(2.75)	(1.01)	(0.28)	0.46
	Free cash flow	(0.54)	3.67	(0.55)	1.96	7.50	1.80	(3.43)	(5.04)	0.82	3.64
	Book value	14.83	21.83	20.18	21.14	27.46	30.26	27.70	12.68	9.11	9.77
	Shares, m	40	42	50	52	53	54	50	51	53	54
Valuation, ×
Valuation, ×	P/E	28.90	24.60	47.42	50.90	15.50	10.04	0.00	0.00	0.00	13.01
	P/S	2.73	3.57	3.80	2.51	3.04	1.31	0.54	0.13	0.49	0.89
	P/B	2.24	2.20	2.94	2.55	3.26	1.44	0.43	0.20	1.05	1.27
	EV/Sales	2.69	3.28	4.67	3.09	3.20	1.46	1.22	0.84	1.02	1.38
	EV/FCF	(60.88)	12.01	(131.85)	33.85	12.61	26.95	(9.11)	(3.42)	24.38	5.26
Cash, $m
Cash, $m	Operating cash flow	55	208	42	188	536	320	(34)	(206)	59	171
	Capex	(76)	(55)	(69)	(87)	(141)	(224)	(138)	(52)	(15)	24
	Free cash flow	(22)	153	(28)	101	395	96	(172)	(258)	44	195
Balance, $m
Balance, $m	Working capital	404	385	420	470	811	898	(18)	28	436	530
	Total debt	268	14	795	811	880	841	1,406	860	664	572
	Net debt	(3)	(166)	682	643	259	265	763	749	558	363
	Shareholders’ equity	596	912	1,011	1,089	1,447	1,619	1,388	649	483	523
Returns, %
Returns, %	ROA	5.16	8.10	3.80	2.39	11.71	7.51	(6.91)	(30.48)	(11.86)	3.88
	ROIC	11.12	10.41	3.31	4.12	15.90	11.33	(4.94)	(32.48)	(6.53)	7.06
	ROE	8.25	10.95	6.52	5.19	24.07	14.32	(14.08)	(74.67)	(33.67)	10.46

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)	Compare
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)	Compare
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)	Compare
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%	Compare
Median of peers	$463.1M	—	—	+19.82%	—	+20.62%	40.50%	(16.53%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Emergent Biosolutions Inc. (EBS) key facts

Concern: Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024.
Emergent Biosolutions Inc. (EBS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, EBS traded at $6.38, a market capitalization of $368.1 million.
Return on equity was 10.5% and debt-to-equity 1.70.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 1.63 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.